Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5687-5692

  Papp Wallace, Krisztina M ^a,b   Senkfor, Baui ^a   Gatta, Julian ^a   Chai, Weirui ^c   Taracila, Magdalena A ^b   Shanmugasundaram, Veerabahu ^d   Han, Seungil ^d   Zaniewski, Richard P ^d   Lacey, Brian M ^d   Tomaras, Andrew P ^d   Skalweit, Marion J ^a,b   Harris, Michael E ^b   Rice, Louis B ^e   Buynak, John D ^c   Bonomo, Robert A ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

^d PFIZER INC   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BOCILLIN; CEFALOTIN; CEFOTAXIME; CLAVULANIC ACID; DORIPENEM; OXACILLIN; SULBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER; ACINETOBACTER BAUMANNII; AMPICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; BIOLOGICAL ASSAY; BORON COMPOUNDS; ENZYME INHIBITORS; HUMANS; KINETICS; MOLECULAR DOCKING SIMULATION; PENICILLIN-BINDING PROTEINS; PENICILLINS; SOLUBILITY; SUBSTRATE SPECIFICITY; SULBACTAM;

EID: 84868015162     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01027-12     Document Type: Article

References (51)

1. Amudhan SM, Sekar U, Arunagiri K, Sekar B. 2011. OXA β-lactamase- mediated carbapenem resistance in Acinetobacter baumannii. Indian J. Med. Microbiol. 29:269-274.
2. Baang JH, et al. 2012. Longitudinal epidemiology of multidrug-resistant (MDR) Acinetobacter species in a tertiary care hospital. Am. J. Infect. Control 40:134-137.
3. Balaji V, Jeremiah SS, Baliga PR. 2011. Polymyxins: antimicrobial susceptibility concerns and therapeutic options. Indian J. Med. Microbiol. 29:230-242.
4. Beceiro A, et al. 2009. In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii. Antimicrob. Agents Chemother. 53:4298 - 4304.
5. Chung DR, et al. 2011. High prevalence of multidrug-resistant nonfer-menters in hospital-acquired pneumonia in Asia. Am. J. Respir. Crit. Care Med. 184:1409-1417.
6. Clark RB. 1996. Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa outer membrane protein. J. Antimicrob. Chemother. 38:245-251.
7. Copeland RA. 2000. Enzymes: a practical introduction to structure, mechanism, and data analysis. John Wiley & Sons, Inc., New York, NY.
8. Dallo SF, Weitao T. 2010. Insights into Acinetobacter war-wound infections, biofilms, and control. Adv. Skin Wound Care 23:169-174.
9. Davies TA, et al. 2011. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J. Antimicrob. Chemother. 66:2298-2307.
10. Doyle JS, Buising KL, Thursky KA, Worth LJ, Richards MJ. 2011. Epidemiology of infections acquired in intensive care units. Semin. Respir. Crit. Care Med. 32:115-138.
11. Espinal P, Roca I, Vila J. 2011. Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter. Future Microbiol. 6:495-511.
12. Esterly JS, Richardson CL, Eltoukhy NS, Qi C, Scheetz MH. 2011. Genetic mechanisms of antimicrobial resistance of Acinetobacter baumannii. Ann. Pharmacother. 45:218-228.
13. Fali A, du Plessis M, Wolter N, Klugman KP, von Gottberg A. 2010. Single report of β-lactam resistance in an invasive Haemophilus influenzae isolate from South Africa mediated by mutations in penicillin-binding protein 3, 2003-2008. Int. J. Antimicrob. Agents 36:480-482.
14. Fernandez-Cuenca F, et al. 2003. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 51:565-574.
15. Fisher JF, Mobashery S. 2010. Host-guest chemistry of the peptidoglycan. J. Med. Chem. 53:4813-4829.
16. Garnacho-Montero J, Amaya-Villar R. 2010. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr. Opin. Infect. Dis. 23:332-339.
17. Gehrlein M, Leying H, Cullmann W, Wendt S, Opferkuch W. 1991. Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. Chemotherapy 37:405-412.
18. Georgopapadakou NH. 1993. Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob. Agents Chemother. 37:2045-2053.
19. Georgopapadakou NH, Liu FY. 1980. Penicillin-binding proteins in bacteria. Antimicrob. Agents Chemother. 18:148-157.
20. Goffin C, Ghuysen JM. 1998. Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol. Mol. Biol. Rev. 62:1079-1093.
21. Gupta A, et al. 2011. Incidence, risk stratification, antibiogram of pathogens isolated and clinical outcome of ventilator associated pneumonia. Indian J. Crit. Care Med. 15:96-101.
22. Gupta A, et al. 2011. Burden of healthcare-associated infections in a paediatric intensive care unit of a developing country: a single centre experience using active surveillance. J. Hosp. Infect. 78:323-326.
23. Han S, et al. 2011. Distinctive attributes of β-lactam target proteins in Acinetobacter baumannii relevant to development of new antibiotics. J. Am. Chem. Soc. 133:20536-20545.
24. Hujer AM, et al. 2005. Structure-activity relationships of different β-lactam antibiotics against a soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase. Antimicrob. Agents Chemother. 49:612-618.
25. Hujer KM, et al. 2006. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 50:4114-4123.
26. Kiratisin P, Apisarnthanarak A, Kaewdaeng S. 2010. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int. J. Antimicrob. Agents 36:243-246.
27. Labia R, Morand A, Lelievre V, Mattioni D, Kazmierczak A. 1986. Sulbactam: biochemical factors involved in its synergy with ampicillin. Rev. Infect. Dis. 8(Suppl 5):S496-S502.
28. Limansky AS, Mussi MA, Viale AM. 2002. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J. Clin. Microbiol. 40:4776-4778.
29. Llarrull LI, Fisher JF, Mobashery S. 2009. Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new β-lactams that meet the challenge. Antimicrob. Agents Chemother. 53: 4051-4063.
30. Luo L, et al. 2011. Efflux pump overexpression in conjunction with alternation of outer membrane protein may induce Acinetobacter baumannii resistant to imipenem. Chemotherapy 57:77-84.
31. Marchaim D, et al. 2011. Outcomes and genetic relatedness of carbap-enem-resistant Enterobacteriaceae at Detroit Medical Center. Infect. Control Hosp. Epidemiol. 32:861-871.
32. Marra AR, et al. 2011. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J. Clin. Microbiol. 49:1866-1871.
33. Masson JM, Kazmierczak A, Labia R. 1983. Interactions of clavulanic acid and sulbactam with penicillin binding proteins. Drugs Exp. Clin. Res. IX:513-518.
34. Michalopoulos A, Falagas ME. 2010. Treatment of Acinetobacter infections. Expert Opin. Pharmacother. 11:779-788.
35. Mushtaq S, Warner M, Livermore D. 2010. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J. Antimicrob. Chemother. 65:266-270.
36. Neonakis IK, Spandidos DA, Petinaki E. 2011. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int. J. Antimicrob. Agents 37:102-109.
37. Obara M, Nakae T. 1991. Mechanisms of resistance to β-lactam antibiotics in Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 28:791-800.
38. Pongpech P, et al. 2010. Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii. J. Med. Assoc. Thailand 93:161-171.
39. Quale J, Bratu S, Landman D, Heddurshetti R. 2003. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin. Infect. Dis. 37:214-220.
40. Ramirez MS, Adams MD, Bonomo RA, Centron D, Tolmasky ME. 2011. Genomic analysis of Acinetobacter baumannii A118 by comparison of optical maps: identification of structures related to its susceptibility phenotype. Antimicrob. Agents Chemother. 55:1520-1526.
41. Sanchez A, Gattarello S, Rello J. 2011. New treatment options for infections caused by multiresistant strains of Pseudomonas aeruginosa and other nonfermenting Gram-negative bacilli. Semin. Respir. Crit. Care Med. 32:151-158.
42. San Millan A, et al. 2011. Contribution of ROB-1 and PBP3 mutations to the resistance phenotype of a β-lactamase-positive amoxicillin/clavulanic acid-resistant Haemophilus influenzae carrying plasmid pB1000 in Italy. J. Antimicrob. Chemother. 66:96-99.
43. Sheng WH, et al. 2011. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against car-bapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn. Microbiol. Infect. Dis. 70: 380-386.
44. Spratt BG. 1977. Properties of the penicillin-binding proteins of Escherichia coli K12. Eur. J. Biochem. 72:341-352.
45. Suh B, Shapiro T, Jones R, Satishchandran V, Truant AL. 1995. In vitro activity of β-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn. Microbiol. Infect. Dis. 21:111-114.
46. Towner KJ. 2009. Acinetobacter: an old friend, but a new enemy. J. Hosp. Infect. 73:355-363.
47. Urban C, et al. 1993. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J. Infect. Dis. 167:448-451.
48. Urban C, Go E, Mariano N, Rahal JJ. 1995. Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and imipenem-susceptible Acinetobacter baumannii. FEMS Microbiol. Lett. 125:193-198.
49. Zapun A, Contreras-Martel C, Vernet T. 2008. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol. Rev. 32:361-385.
50. Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. 2010. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev. Anti Infect. Ther. 8:71-93.
51. Zhao G, Meier TI, Kahl SD, Gee KR, Blaszczak LC. 1999. Bocillin FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins. Antimicrob. Agents Chemother. 43:1124-1128.